Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 6:11:556962.
doi: 10.3389/fendo.2020.556962. eCollection 2020.

From Influenza Virus to Novel Corona Virus (SARS-CoV-2)-The Contribution of Obesity

Affiliations
Review

From Influenza Virus to Novel Corona Virus (SARS-CoV-2)-The Contribution of Obesity

Indranil Bhattacharya et al. Front Endocrinol (Lausanne). .

Abstract

From the beginning of 2020, the governments and the health systems around the world are tackling infections and fatalities caused by the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) resulting in the coronavirus disease 2019 (COVID-19). This virus pandemic has turned more complicated as individuals with co-morbidities like diabetes, cardiovascular conditions and obesity are at a high risk of acquiring infection and suffering from a more severe course of disease. Prolonged viral infection and obesity are independently known to lower the immune response and a combination can thus result in a "cytokine storm" and a substantial weakening of the immune system. With the rise in obesity cases globally, the chances that obese individuals will acquire infection and need hospitalization are heightened. In this review, we discuss why obesity, a low-grade chronic inflammation, contributes toward the increased severity in COVID-19 patients. We suggest that increased inflammation, activation of renin-angiotensin-aldosterone system, elevated adipokines and higher ectopic fat may be the factors contributing to the disease severity, in particular deteriorating the cardiovascular and lung function, in obese individuals. We look at the many lessons learnt from the 2009 H1N1 influenza A pandemic and relate it to the very little but fast incoming information that is available from the SARS-CoV-2 infected individuals with overweight and obesity.

Keywords: COVID-19; SARS-CoV-2; adipocytes; adiposity; novel corona virus; obesity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Excess adiposity provides an ideal setting to promote viral infection. We propose that obesity and its associated conditions elevate the cytokines, adipokines and RAAS and increase ectopic fat accumulation. When infection sets in, in this case with SARS-COV-2, through ACE2 receptor on the adipose tissue, the lungs, the heart and the blood vessels, the virus enters, mediates a cytokine storm and creates an imbalance in AngII/ACE-2 levels, elevates leptin levels and lowers anti-viral molecules like IFNs. Moreover, adipose tissue a might serve as a reservoir for viral persistence, which could be the possible source of continuous viral shedding and systemic inflammation. The combination of all the factors deteriorates lungs and the cardiovascular system, weakens the immune response, and promotes viral shedding. Yellow circle indicate adipocytes, red marks indicate inflammatory cells, upwards and downwards arrows indicates upregulation or downregulation of molecules and/ or effect.

Similar articles

  • Obesity and COVID-19.
    Azzolino D, Cesari M. Azzolino D, et al. Front Endocrinol (Lausanne). 2020 Sep 30;11:581356. doi: 10.3389/fendo.2020.581356. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33101213 Free PMC article. No abstract available.
  • Influenza immunization and COVID-19.
    Maltezou HC, Theodoridou K, Poland G. Maltezou HC, et al. Vaccine. 2020 Sep 3;38(39):6078-6079. doi: 10.1016/j.vaccine.2020.07.058. Epub 2020 Jul 29. Vaccine. 2020. PMID: 32773245 Free PMC article. No abstract available.
  • COVID-19: a conundrum to decipher.
    Deshmukh V, Tripathi SC, Pandey A, Deshmukh V, Vykoukal J, Patil A, Sontakke B. Deshmukh V, et al. Eur Rev Med Pharmacol Sci. 2020 May;24(10):5830-5841. doi: 10.26355/eurrev_202005_21378. Eur Rev Med Pharmacol Sci. 2020. PMID: 32495923
  • Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics.
    Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, Storgaard M, Al Khalili S, Simonsen L. Petersen E, et al. Lancet Infect Dis. 2020 Sep;20(9):e238-e244. doi: 10.1016/S1473-3099(20)30484-9. Epub 2020 Jul 3. Lancet Infect Dis. 2020. PMID: 32628905 Free PMC article. Review.
  • The COVID-19 pandemic.
    Ciotti M, Ciccozzi M, Terrinoni A, Jiang WC, Wang CB, Bernardini S. Ciotti M, et al. Crit Rev Clin Lab Sci. 2020 Sep;57(6):365-388. doi: 10.1080/10408363.2020.1783198. Epub 2020 Jul 9. Crit Rev Clin Lab Sci. 2020. PMID: 32645276 Review.

Cited by

References

    1. Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, et al. . Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. (2017) 377:13–27. 10.1056/NEJMoa1614362 - DOI - PMC - PubMed
    1. Ford ND, Patel SA, Narayan KM. Obesity in low- and middle-income countries: burden, drivers, and emerging challenges. Annu Rev Public Health. (2017) 38:145–64. 10.1146/annurev-publhealth-031816-044604 - DOI - PubMed
    1. Sung H, Siegel RL, Torre LA, Pearson-Stuttard J, Islami F, Fedewa SA, et al. . Global patterns in excess body weight and the associated cancer burden. CA Cancer J Clin. (2019) 69:88–112. 10.3322/caac.21499 - DOI - PubMed
    1. Bluher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. (2019) 15:288–98. 10.1038/s41574-019-0176-8 - DOI - PubMed
    1. Mafort TT, Rufino R, Costa CH, Lopes AJ. Obesity: systemic and pulmonary complications, biochemical abnormalities, and impairment of lung function. Multidiscip Respir Med. (2016) 11:28. 10.1186/s40248-016-0066-z - DOI - PMC - PubMed

MeSH terms